Who owns KALARIS THERAPEUTICS INC COM?
- Ticker: KLRS
- CUSIP Number: 482929106
Tip: Access positions for across all investors
Analyze quarterly positions in Kalaris Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Kalaris Therapeutics stock
Who bought or sold KALARIS THERAPEUTICS INC COM this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Samsara BioCapital | 11M | $66M | 0% | Sep 2025 |
|
| Tang Capital Management | 418k | $2.4M | 16% | Sep 2025 |
|
| Siren | 318k | $1.8M | 13% | Sep 2025 |
|
| Woodline Partners | 241k | $1.4M | 100% | Sep 2025 |
|
| Vanguard Group | 203k | $1.2M | 56% | Sep 2025 |
|
| Renaissance Technologies | 113k | $652k | 17% | Sep 2025 |
|
| Redmile Group | 83k | $480k | 0% | Sep 2025 |
|
| Geode Capital Management | 65k | $373k | 153% | Sep 2025 |
|
| BlackRock | 40k | $233k | 6% | Sep 2025 |
|
| Squarepoint Ops | 40k | $232k | -32% | Sep 2025 |
|
| Fortis Capital Advisors | 40k | $231k | 100% | Sep 2025 |
|
| Belpointe Asset Management | 40k | $231k | 100% | Sep 2025 |
|
| Millennium Management | 25k | $144k | -54% | Sep 2025 |
|
| State Street Corporation | 23k | $131k | 111% | Sep 2025 |
|
| Bridgeway Capital Management | 23k | $130k | 100% | Sep 2025 |
|
| Goldman Sachs Group | 23k | $130k | 100% | Sep 2025 |
|
| Rbf Capital | 17k | $101k | 0% | Sep 2025 |
|
| Marshall Wace | 14k | $82k | 0% | Sep 2025 |
|
| Johnson Financial Group | 10k | $58k | 100% | Sep 2025 |
|
| FMR | 7.8k | $45k | 0% | Sep 2025 |
|
| UBS Group | 5.3k | $30k | 28% | Sep 2025 |
|
| Morgan Stanley | 2.0k | $5.2k | 100% | Jun 2025 |
|
| Federated Investors | 578.00 | $3.3k | -9% | Sep 2025 |
|
| Strengthening Families & Communities | 268.00 | $1.5k | 100% | Sep 2025 |
|
| Bnp Paribas Arbitrage, Snc | 141.00 | $814.994100 | 0% | Sep 2025 |
|
| Royal Bank of Canada | 85.00 | $0 | 0% | Sep 2025 |
|
| Jpmorgan Chase & Co | 50.00 | $289.130000 | -83% | Sep 2025 |
|
| Parallel Advisors | 49.00 | $282.999500 | 0% | Sep 2025 |
|
| Farther Finance Advisors | 33.00 | $191.000700 | 0% | Sep 2025 |
|
| SBI Securities | 8.00 | $46.000000 | -20% | Sep 2025 |
|
Who sold out of Kalaris Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Octagon Capital Advisors | Jun 2025 | 360k | $961k |
| Gilead Sciences | Jun 2025 | 318k | $849k |
| XTX Topco | Jun 2025 | 24k | $65k |
| Two Sigma Advisers | Jun 2025 | 20k | $54k |
| Raymond James Financial | Jun 2025 | 2.6k | $7.0k |
| Tower Research Capital | Jun 2025 | 2.2k | $5.7k |